NCT03192813已完成不适用
Safety and Efficacy Comparison Of Two TAVI Systems in a Prospective Randomized Evaluation II: A Randomized, Controlled, Non-inferiority Trial Evaluating Safety and Clinical Efficacy of the Symetis ACURATE Neo Compared to the Medtronic Evolut R Bioprosthesis in Transfemoral Transcatheter Aortic Valve Implantation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Ceric Sàrl
- 入组人数
- 796
- 试验地点
- 23
- 主要终点
- Composite of all-cause mortality or stroke rates
研究概览
简要总结
Current care randomized clinical trial comparing the CE marked Symetis ACURATE neo™ Aortic Bioprosthesis and ACURATE TF™ Transfemoral Delivery System with the CE marked Medtronic CoreValve Evolut R TAVI system (or any future CE-marked CoreValve versions).
详细描述
Transcatheter aortic valve implantation (TAVI) is an established and valuable treatment option for patients with severe symptomatic aortic stenosis and at high surgical risk for aortic valve replacement. The use of TAVI is rapidly expanding worldwide and its indications are widening into intermediate and lower risk populations. However, device comparisons by use of randomized trials are scarce in particular for newer generation transcatheter valves.
The Symetis ACURATE neo™, a self-expanding transcatheter valve delivered via transfemoral access, is a second-generation device that gained CE mark approval in June 2014.
The SCOPE-II trial will compare the safety and performance of the Symetis ACURATE neo™ with the self-expanding Medtronic Evolut R system, a widely used and well-established transcatheter heart valve, which obtained CE mark in 8NOV2006 and HAS approval on 13JAN2015.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 75 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient with severe symptomatic aortic stenosis defined by a mean aortic gradient > 40 mmHg or peak jet velocity > 4.0 m/s or an aortic valve area (AVA) < 1cm2 or AVA indexed to body surface area (BSA) of <0.6 cm2/m2
- •Patient is symptomatic (heart failure with New York Heart Association (NYHA) Functional Class > I, angina or syncope)
- •Patients are considered at high risk for mortality with conventional surgical aortic valve replacement as assessed by a Heart Team consisting of a cardiologist and surgeon or as confirmed by a logistic EuroSCORE I > 20% and / or STS score > 10%.
- •Aortic annulus diameter ranging from 21 to 26mm and perimeter rage from 66 - 81.7mm , based on ECG-gated multi-slice computed tomographic measurements. Findings of TTE, TEE and conventional aortography should be integrated in the anatomic assessment.
- •Arterial aorto-iliac-femoral axis suitable for transfemoral access as assessed by conventional angiography and/or multi-detector computed tomographic angiography (access vessel diameter ≥ 6mm)
- •Patient understands the purpose, the potential risks as well as benefits of the trial and is willing to participate in all parts of the follow-up
- •Patient age 75 years or older
- •Patient has given written consent to participate in the trial
排除标准
- •Severely reduced left ventricular (LV) function (ejection fraction <20%)
- •Pre-existing prosthetic heart valve in aortic and/or mitral position
- •Participation in another trial, which would lead to deviations in the preparation or performance of the intervention or the post-implantation management from this protocol
- •Severe coagulation conditions
- •Inability to tolerate anticoagulation therapy
- •Contraindication to contrast media or allergy to nitinol
- •Active infection, including endocarditis
- •Congenital aortic stenosis or unicuspid or bicuspid aortic valve
- •Non-valvular aortic stenosis
- •Hypertrophic obstructive cardiomyopathy
- •New or untreated echocardiographic evidence of intracardiac mass, thrombus, or vegetation
- •Non-calcific acquired aortic stenosis
- •Severe eccentricity of calcification
- •Anatomy not appropriate for transfemoral implant due to size, disease and degree of calcification or tortuosity of the aorta or ilio-femoral arteries
- •Severe mitral regurgitation
结局指标
主要结局
Composite of all-cause mortality or stroke rates
时间窗: 1 year
The primary objective is to compare the composite of all-cause mortality or stroke rates at 1 year (powered for non-inferiority).
次要结局
- Annular rupture/dissection at 30 days(30 days)
- Left ventricular perforation at 30 days(30 days)
- Stroke at 30 days(30 days)
- Cardiac Tamponade at 30 days(30 days)
- Valve malpositioning at 30 days(30 days)
- Implantation of multiple valves (TAV-in-TAV deployment) at 30 days(30 days)
- Conversion to open heart surgery at 30 days(30 days)
- Intra-procedural mortality (during index procedure)(Procedurally)
- New permanent pacemaker rate(30 days)
- Peri-procedural myocardial infarction at 30 days(30 days)
- All cause mortality at 30 days(30 days)
- Myocardial infarction at 30 days and 1 year(30 days and 1 year)
- Endocarditis at 30 days and 1 year(30 days and 1 year)
- New pacemaker implantation at 1 year(1 year)
- Any arrhythmia resulting in hemodynamic instability or requiring therapy at 30 days and 1 year(30 days and 1 year)
- Echocardiographic endpoint (2)(Post-procedurally [day 1 to 7], at 30 days, 1 year)
- Echocardiographic endpoint (3)(Post-procedurally [day 1 to 7], at 30 days, 1 year)
- Echocardiographic endpoint (4)(Post-procedurally [day 1 to 7], at 30 days, 1 year)
- Composite of all-cause mortality or disabling stroke at 30 days and 1 year(30 days and 1 year)
- Valve related dysfunction requiring repeat procedure at 30 days and 1 year(30 days and 1 year)
- Echocardiographic endpoint (7)(Post-procedurally [day 1 to 7], at 30 days, 1 year)
- Echocardiographic endpoint (9)(Post-procedurally [day 1 to 7], at 30 days, 1 year)
- Procedural mortality (up to 72 hours after procedure)(Procedurally and up to 72 hours post-procedurally)
- All stroke (disabling/non disabling) at 30 days and 1 year(30 days and 1 year)
- Life-threatening/major bleeding at 30 days and 1 year(30 days and 1 year)
- Echocardiographic endpoint (10)(Post-procedurally [day 1 to 7], at 30 days, 1 year)
- Mortality (cardiac/non-cardiac) at 30 days and 1 year(30 days and 1 year)
- New AV-conduction disturbances at 30 days and 1 year(30 days and 1 year)
- Echocardiographic endpoint (11)(Post-procedurally [day 1 to 7], at 30 days, 1 year)
- Hospitalization for valve-related symptoms or worsened congestive heart at 30 days and 1 year(30 days and 1 year)
- Valve thrombosis at 30 days and 1 year(30 days and 1 year)
- VARC-2 combined endpoints at 30 days(30 days)
- Time-related valve safety at 1 year(1 year)
- Echocardiographic endpoint (1)(Post-procedurally [day 1 to 7], at 30 days, 1 year)
- Echocardiographic endpoint (6)(Post-procedurally [day 1 to 7], at 30 days, 1 year)
- Echocardiographic endpoint (5)(Post-procedurally [day 1 to 7], at 30 days, 1 year)
- Echocardiographic endpoint (8)(Post-procedurally [day 1 to 7], at 30 days, 1 year)
研究者
研究点 (23)
Loading locations...
相似试验
已完成
不适用
Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis.Aortic Valve StenosisNCT03011346Insel Gruppe AG, University Hospital Bern739
已完成
不适用
ACURATE Neo™ AS Aortic Bioprosthesis for Implantation Using the ACURATE neoTM AS TF Transfemoral Delivery System in Patients With Severe Aortic StenosisAortic StenosisNCT02909556Symetis SA120
已完成
不适用
ACURATE Neo™ Aortic Bioprosthesis for Implantation Using the ACURATE TA™ LP Transapical Delivery System in Patients With Severe Aortic StenosisAortic StenosisNCT02986737Symetis SA15
已完成
不适用
ACURATE™ Transapical Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis (2010-01)Aortic Symptomatic StenosisNCT03143673Symetis SA50
已完成
不适用
ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000Heart Valve DiseasesNCT01116024Medtronic Cardiovascular173